Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Phase 1

Active, not recruiting

Conditions: Desmoplastic Small Round Cell Tumor

Interventions: Drug: Ramucirumab
Drug: Cyclophosphamide
Drug: Vinorelbine

First Posted Date: 2019-10-30

Last Posted Date: 2024-11-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 34

Registration Number: NCT04145349

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 19 locations

Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy

Conditions: Microbiota

Interventions: Drug: cyclophosphamide

First Posted Date: 2019-10-25

Last Posted Date: 2019-10-25

Lead Sponsor: First Affiliated Hospital of Harbin Medical University

Target Recruit Count: 80

Registration Number: NCT04138979

Locations: 🇨🇳
First affiliated hospital of Harbin medical university, Harbin, Heilongjiang, China

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Early Phase 1

Active, not recruiting

Conditions: Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
Plasmablastic Lymphoma

Interventions: Drug: Cyclophosphamide
Biological: Daratumumab
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Prednisone
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-16

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 15

Registration Number: NCT04139304

Locations: 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 5 locations

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

First Posted Date: 2019-10-22

Last Posted Date: 2020-09-04

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT04135092

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Phase 3

Completed

Conditions: Primary Breast Cancer

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: 5-fluorouracil

First Posted Date: 2019-10-15

Last Posted Date: 2020-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 2079

Registration Number: NCT04127019

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Phase 2

Terminated

Conditions: Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Nivolumab
Drug: Ixazomib
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2019-10-08

Last Posted Date: 2023-08-21

Lead Sponsor: Andrew Yee, MD

Target Recruit Count: 2

Registration Number: NCT04119336

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Mass General/North Shore Cancer Center, Danvers, Massachusetts, United States

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Pathologic Stage IIIC Cutaneous Melanoma AJCC V8
Pathologic Stage IV Cutaneous Melanoma AJCC V8
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Uveal Melanoma
Acral Melanoma
Neuroendocrine Tumors
Paraganglioma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Fludeoxyglucose F-18
Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2019-10-08

Last Posted Date: 2024-12-11

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT04119024

Locations: 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Phase 1

Terminated

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Interventions: Biological: MB-102
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-09-30

Last Posted Date: 2024-07-22

Lead Sponsor: Mustang Bio

Target Recruit Count: 3

Registration Number: NCT04109482

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: paclitaxel (PTX)
Biological: nivolumab
Other: nivolumab placebo
Drug: anthracycline
Drug: cyclophosphamide
Drug: Endocrine Therapy
Procedure: Surgery

First Posted Date: 2019-09-30

Last Posted Date: 2025-01-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 521

Registration Number: NCT04109066

Locations: 🇫🇷
Local Institution - 0024, Brest, France
🇫🇷
Local Institution - 0162, Clermont-Ferrand, France
🇫🇷
Local Institution - 0153, Lyon, France

and more 229 locations

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Phase 1

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: LY3295668 Erbumine
Drug: Topotecan
Drug: Cyclophosphamide

First Posted Date: 2019-09-26

Last Posted Date: 2024-08-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 71

Registration Number: NCT04106219

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇧🇪
UZ Gent, Gent, Oost-Vlaanderen, Belgium
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

and more 14 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy